We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+24.48%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.92%
AUM
$72.6B
AUM Growth
+$8.69B
(+14%)
Cap. Flow
+$958M
Cap. Flow % of AUM
Cap. Flow %
1.32%
Top 10 Holdings %
Top 10 Hldgs %
12.01%
Holding
3,761
New
548
Increased
1,084
Reduced
1,502
Closed
621
Avg Time Held
3.5
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 2 |
NVIDIA
NVDA
|
+$938M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$639M |
| 4 |
Netflix
NFLX
|
+$598M |
| 5 |
Amazon
AMZN
|
+$575M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.46B |
| 2 |
Sandisk
SNDK
|
+$1.13B |
| 3 |
Apple
AAPL
|
+$426M |
| 4 |
Linde
LIN
|
+$316M |
| 5 |
Vertiv
VRT
|
+$297M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.58% |
| 2 | Healthcare | 14.83% |
| 3 | Consumer Discretionary | 11.24% |
| 4 | Industrials | 10.49% |
| 5 | Communication Services | 8.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1826
Forward Air
FWRD
$528M
| $2.58M | ﹤0.01% |
190,739
-20,800
| -10% | -$310K |
2026 Q1
1 quarter
|
|
1827
Skeena Resources
SKE
$3.61B
| $2.56M | ﹤0.01% |
+96,200
| New | +$2.89M |
2026 Q2
0 quarters
|
|
1828
Xerox
XRX
$366M
| $2.56M | ﹤0.01% |
817,928
+172,304
| +27% | +$430K |
2025 Q3
3 quarters
|
|
1829
First Community Bankshares
FCBC
$930M
| $2.55M | ﹤0.01% |
57,492
+2,304
| +4% | +$99K |
2013 Q2
52 quarters
|
|
1830
Protalix BioTherapeutics
PLX
$207M
| $2.55M | ﹤0.01% |
1,096,000
-128,800
| -11% | -$273K |
2022 Q1
17 quarters
|
|
1831
Marchex
MCHX
$56.8M
| $2.54M | ﹤0.01% |
1,576,464
-29,440
| -2% | -$47.3K |
2013 Q2
52 quarters
|
|
1832
ProShares UltraShort QQQ
QID
$247M
| $2.53M | ﹤0.01% |
+186,600
| New | +$3.01M |
2026 Q2
0 quarters
|
|
1833
Tigo Energy
TYGO
$71.1M
| $2.53M | ﹤0.01% |
1,084,700
-214,177
| -16% | -$806K |
2025 Q2
4 quarters
|
|
1834
Climb Bio
CLYM
$605M
| $2.51M | ﹤0.01% |
192,700
-24,600
| -11% | -$254K |
2023 Q4
10 quarters
|
|
1835
SIFCO Industries
SIF
$126M
| $2.51M | ﹤0.01% |
107,334
+51,500
| +92% | +$938K |
2013 Q2
52 quarters
|
|
1836
Comp X International
CIX
$442M
| $2.51M | ﹤0.01% |
100,749
-6,200
| -6% | -$150K |
2013 Q2
52 quarters
|
|
1837
Citizens Community Bancorp
CZWI
$207M
| $2.51M | ﹤0.01% |
107,200
+53,800
| +101% | +$1.13M |
2023 Q4
10 quarters
|
|
1838
Apollo Global Management
APO
$67.8B
| $2.51M | ﹤0.01% |
21,186
-73,703
| -78% | -$9.27M |
2026 Q1
1 quarter
|
|
1839
NEOS S&P 500 High Income ETF
SPYI
$12.2B
| $2.51M | ﹤0.01% |
+47,200
| New | +$2.48M |
2026 Q2
0 quarters
|
|
1840
Oak Valley Bancorp
OVLY
$288M
| $2.5M | ﹤0.01% |
73,973
+38,598
| +109% | +$1.3M |
2019 Q4
26 quarters
|
|
1841
DELISTED
Taylor Morrison
TMHC
| $2.49M | ﹤0.01% |
+34,753
| New | +$2.21M |
2026 Q2
0 quarters
|
|
1842
Apyx Medical
APYX
$102M
| $2.49M | ﹤0.01% |
554,278
+251,883
| +83% | +$999K |
2015 Q1
45 quarters
|
|
1843
Monte Rosa Therapeutics
GLUE
$948M
| $2.48M | ﹤0.01% |
102,500
-276,600
| -73% | -$5.23M |
2026 Q1
1 quarter
|
|
1844
Mitek Systems
MITK
$806M
| $2.48M | ﹤0.01% |
123,200
-307,393
| -71% | -$4.77M |
2019 Q1
29 quarters
|
|
1845
Diversified Healthcare Trust
DHC
$1.91B
| $2.48M | ﹤0.01% |
266,503
-48,497
| -15% | -$397K |
2025 Q1
5 quarters
|
|
1846
Vanguard Morningstar Small-Cap Growth ETF
VBK
$22.2B
| $2.47M | ﹤0.01% |
6,760
+5,080
| +302% | +$1.73M |
2025 Q4
2 quarters
|
|
1847
Organogenesis Holdings
ORGO
$133M
| $2.47M | ﹤0.01% |
1,017,113
-51,425
| -5% | -$126K |
2019 Q4
26 quarters
|
|
1848
AutoNation
AN
$5.35B
| $2.47M | ﹤0.01% |
13,300
-78,200
| -85% | -$15.3M |
2025 Q2
4 quarters
|
|
1849
Alphatec Holdings
ATEC
$1.75B
| $2.46M | ﹤0.01% |
284,500
-770,600
| -73% | -$7.02M |
2023 Q2
12 quarters
|
|
1850
Phathom Pharmaceuticals
PHAT
$567M
| $2.46M | ﹤0.01% |
226,400
-79,400
| -26% | -$906K |
2026 Q1
1 quarter
|
|
Similar funds
Jim Simons's Q2 2026 Portfolio in Review
As of Q2 2026, Jim Simons held 3,761 positions worth $72.6B, up 14% from $63.9B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q2 2026 filing shows 548 new, 1,084 increased, 1,502 reduced and 621 closed positions. Its largest new stake was Amazon: 2,290,710 shares worth $546M. The largest sale was Micron Technology, an estimated $1.46B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q2 2026 buy was Amazon: 2,290,710 shares worth $546M.
- Jim Simons added most to Meta Platforms (Facebook) in Q2 2026, an estimated $1.08B increase.
- Jim Simons's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $1.46B.
- Jim Simons fully exited Applovin in Q2 2026, selling an estimated $174M.
- Jim Simons's ten largest holdings make up 12% of its $72.6B portfolio in Q2 2026.
- Jim Simons opened 548 new positions and closed 621 in Q2 2026.
- Jim Simons's portfolio value rose 14% quarter-over-quarter to $72.6B.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.